best pokies mobile real money Betfred Casino mobilen Bannern usa kunden Weakness in NASDAQ and Earnings Miss Gives an Excuse To Sell

Online Casino usa zju The Blistering 14% July Run in Biotech Comes to an End

Dvd brenner Schlitz It was inevitable that something would cause biopharmaceutical stocks to falter. Today it was overall weakness in the market and a miss by the highest of high fliers Regeneron Pharmaceuticals (REGN $253) off 6.8% on double average volume, but still up 48% YTD. The stock hit a double top at the $280 level.Q2 Sales of Eyelea Injection for wet age-related macular degeneration were $426M with the Net Forecast for 2013 raised to $1.3-1,35 B. Net Income for Q2 was $198M or an EPS of $1.73. Some analysts expected $1.81 on Sales of $458M.  Many analysts just reiterated outperform and raised their targets based on the pipeline such as Eyelea for DME. Regeneron (REGN) has been on our buy list since 2/2/09 at a price of $17.50

betfair casino welcome bonus Goldman jumped on the negativity with a list of 40 overvalued stocks including Celgene Jackpot Spielautomaten merkur trgovina Mariborski grbx (CELG) down 3.5% but up 80% YTD!

casino rama eap A comparison of Celgene and Regeneron:

wms online slots usa Price              Market Cap            P/S                PE            PEG

casino spindleruv mlyn Hollywood Casino Lawrenceburg Indiana CELG                  $141.75         $60.8B             10.25         41         1.86

Las vegas club casino Casino Online sin registro REGN                  $253              $26.2B             16.55         36.6     1.46

ruby slots casino 0 no deposit bonus codes We all know that valuations are a bad metric in biotech but Celgene (CELG) was an under performer until early January when a few major analysts “discovered” the laggard. Looking at the technicals of CELG it looks like in a sell-off mode  it could back down the $130 level.

Casino slot machine Try to do a financial analysis on this biotech focused on a rare disease for hypercholesterolemia which costs almost $300k/year to treat one patient: Skycity adelaide casino Aegerion (AEGR $91.84) with a market cap of $2.65B and forecasted 2013 $7.7M in Sales. The stock has tripled YTD and will lose $2.16/share in 2013. The bulls are betting on Sales of $176M in 2014.

virgin online casino nj The biopharmaceutical sell-off is gathering steam as we head to the close with many 2%+ movers down. High fliers down are : Albany Molecular (AMRI), Clovis Oncology CLVS) and Pharmacyclics (PCYC).

how to win on casino slot machines We will update this post after the close.

Wall Casino Las Vegas Our mid-cap index of 50 biopharma stocks was down over 2% with only four winners: ARQL,PBYI, PCRX and TRGT. Tools and diagnostics stocks were less impacted in this sell-off. The last correction in biotech was June after a mid-May high nera $187.

Caesar Casino Online Myers We are at all time highs (IBB $200) as of last week. No change in our portfolios but have a 10% cash position.

 

 

Pin It on Pinterest